Archana Thakur

University of Virginia — United States

Medicine · Health Sciences

36h-index3.7kcitations333works0.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Prostate Cancer Treatment and Research(117), Hormonal and reproductive studies(91), CAR-T cell therapy research(89), Immunotherapy and Immune Responses(63), Monoclonal and Polyclonal Antibodies Research(63)

Publications333 total

Supplementary Figure S3 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
2025Open Access
Supplementary Table S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
2025Open Access
Supplementary Figure S1 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
2025Open Access
Supplementary Figure S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
2025Open Access
Supplementary Table S1 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
2025Open Access
Explainable AI For Early Detection Of Sepsis
arXiv (Cornell University)·2025Open Access
LAG3+ CD8+ T cell subset drives HR+/HER2− breast cancer reduction in bispecific antibody armed activated T cell therapy
The Journal of Immunology·2025
Deubiquitinases in metabolic diseases, fibrosis and cancer of the liver
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research·2025· 2 cited
Abstract 4803: Adaptation of headless CAR T cells to tumor microenvironment induces enhance proliferation and anti-tumor activity against solid cancers
Cancer Research·2025
Abstract 7185: Optimization of an epigenetic based combination platform for patients with peripheral t cell lymphoma
Cancer Research·2025
Table S1 from Peripheral Blood IFN Responses to Toll-Like Receptor 1/2 Signaling Associate with Longer Survival in Men with Metastatic Prostate Cancer Treated with Sipuleucel-T
2025Open Access
Figure S1 from Peripheral Blood IFN Responses to Toll-Like Receptor 1/2 Signaling Associate with Longer Survival in Men with Metastatic Prostate Cancer Treated with Sipuleucel-T
2025Open Access
Figure S3 from Peripheral Blood IFN Responses to Toll-Like Receptor 1/2 Signaling Associate with Longer Survival in Men with Metastatic Prostate Cancer Treated with Sipuleucel-T
2025Open Access
Figure S7 from Peripheral Blood IFN Responses to Toll-Like Receptor 1/2 Signaling Associate with Longer Survival in Men with Metastatic Prostate Cancer Treated with Sipuleucel-T
2025Open Access
Figure S5 from Peripheral Blood IFN Responses to Toll-Like Receptor 1/2 Signaling Associate with Longer Survival in Men with Metastatic Prostate Cancer Treated with Sipuleucel-T
2025Open Access
Figure S6 from Peripheral Blood IFN Responses to Toll-Like Receptor 1/2 Signaling Associate with Longer Survival in Men with Metastatic Prostate Cancer Treated with Sipuleucel-T
2025Open Access
Figure S4 from Peripheral Blood IFN Responses to Toll-Like Receptor 1/2 Signaling Associate with Longer Survival in Men with Metastatic Prostate Cancer Treated with Sipuleucel-T
2025Open Access
Figure S2 from Peripheral Blood IFN Responses to Toll-Like Receptor 1/2 Signaling Associate with Longer Survival in Men with Metastatic Prostate Cancer Treated with Sipuleucel-T
2025Open Access
Supplementary Figure S3A from Race-Related Differences in Sipuleucel-T Response among Men with Metastatic Castrate–Resistant Prostate Cancer
2025Open Access
Supplementary Table S2 from Race-Related Differences in Sipuleucel-T Response among Men with Metastatic Castrate–Resistant Prostate Cancer
2025Open Access
page 1 of 17Next →

Frequent Co-authors

Lawrence G. Lum(23), Mark Willcox(10), Aliccia Bollig‐Fischer(8), Fazlul H. Sarkar(8), Dana L. Schalk(8), Hector Biliran(7), D. Joshua Liao(5), Jack Wu(5), Meilang Xue(5), Abhinav Deol(5), Sanjeev Banerjee(4), Joshua D. Liao(4), Yuan Sun(4), Denis Wakefield(4), Andrew R. Lloyd(4), Nerida Cole(4), Zaid Al‐Kadhimi(3), Qin Liu(3), Fiona Stapleton(3), Ulka N. Vaishampayan(3)